GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Xencor Inc.
Xencor is a biotech company that owns a platform for creating improved antibodies. Its share price depends not only on its own developments but also on the success of its numerous partners who use its technology, generating a stream of royalties.
Share prices of companies in the market segment - Oncology immuno-therapy
Xencor is a biotech company developing engineered antibodies to treat cancer and autoimmune diseases. We've categorized it as an "Immuno-Oncology" company. The chart below shows how investors value companies with innovative platforms for developing new classes of drugs.
Broad Market Index - GURU.Markets
Xencor is a biotech company developing engineered antibodies to treat cancer and autoimmune diseases. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
XNCR - Daily change in the company's share price Xencor Inc.
For Xencor, a developer of cancer antibodies, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials and partnerships with major pharmaceutical companies. This metric forms the basis for analyzing biotech platforms on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Xencor, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with XNCR's performance, which hinges on the results of clinical trials of its antibody platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Xencor is a biopharmaceutical company developing bispecific antibodies for cancer treatment. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and dynamics of Xencor stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Xencor Inc.
Xencor is a biotech company that has developed a unique platform for creating antibodies for cancer treatment. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in the potential of its scientific platform.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Xencor, Inc. is a biotech company with a unique platform for creating bispecific antibodies and cytokines for the treatment of cancer and autoimmune diseases. This chart shows how the market views its innovative technology, numerous partnerships, and clinical trial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xencor is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Xencor Inc.
Nurix, a biotech company working in the field of targeted protein degradation, has sharp monthly fluctuations reflecting the publication of clinical trial data. Trial success is key to the company's valuation and determines investor sentiment.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Xencor is developing a new generation of antibodies to treat cancer and autoimmune diseases. The immuno-oncology sector is one of the fastest-growing, but also riskiest, sectors in biotech. The industry's dynamics reflect investors' faith in breakthrough technologies. Xencor's story is one of a race to create effective drugs that could change the treatment paradigm and generate billions in revenue.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies to treat cancer and autoimmune diseases. The company's future depends on the success of its clinical trials and partnerships. The broader market chart serves as just a backdrop to illustrate how its scientific breakthroughs have driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Xencor Inc.
Xencor develops antibodies for the treatment of cancer and autoimmune diseases. The company's weekly stock price is volatile and depends on news about clinical trials and licensing agreements with major pharmaceutical partners.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Xencor is a biotech company developing antibodies. Comparing its weekly performance to the biotech index will reveal how the market views its platform. The chart also shows how news of partnerships with major pharma companies using its technology is driving more stable growth.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Xencor, a biotech company, lives in a world of its own. Its performance is driven by news of partnerships. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
XNCR - Market capitalization of the company Xencor Inc.
Xencor's market capitalization chart tells the story of an innovative platform for creating improved antibodies. The biotech company uses its XmAb technology to develop both its own oncology drugs and in partnership with pharmaceutical giants. Its dynamics visualize how the market values this "antibody factory."
XNCR - Share of the company's market capitalization Xencor Inc. within the market segment - Oncology immuno-therapy
Xencor is a biotech company using its cutting-edge platform to create engineered antibodies to treat cancer and autoimmune diseases. Its market share reflects the value of its technology and numerous partnerships with major pharmaceutical companies. The chart below shows the importance of this "antibody engineer" in modern oncology.
Market capitalization of the market segment - Oncology immuno-therapy
Xencor is a biotech company developing antibodies and cytokines for the treatment of cancer and autoimmune diseases using its XmAb platform. The chart below shows the overall market capitalization of the immuno-oncology sector, reflecting the potential of innovative engineering approaches to create more effective drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows antibody engineering. Xencor is developing "smart" antibodies that can more effectively fight cancer and autoimmune diseases. Its market cap reflects the progress of its technology platform and success in clinical trials. It's a visualization of how the immune system is being "tuned."
Book value capitalization of the company, segment and market as a whole
XNCR - Book value capitalization of the company Xencor Inc.
Xencor's foundation is its XmAb scientific platform for creating bispecific antibodies and cytokines for the treatment of cancer and autoimmune diseases. This represents cutting-edge intellectual capital. The chart shows how the company is building its capital base through partnerships with pharmaceutical giants and developing its own drugs.
XNCR - Share of the company's book capitalization Xencor Inc. within the market segment - Oncology immuno-therapy
Xencor is a biotech company developing novel antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its value lies in its unique engineering platform. The chart shows a minimal share of physical assets, as it is an R&D-focused business.
Market segment balance sheet capitalization - Oncology immuno-therapy
Antibody development, like Xencor's, is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its technological platform. Compared to the capital-intensive pharmaceutical sector, the company's partnership- and licensing-based model is highly capital-efficient.
Book value of all companies included in the broad market index - GURU.Markets
Xencor's assets are not factories, but cutting-edge laboratories and a technology platform for engineering antibodies to improve their effectiveness in the fight against cancer and autoimmune diseases. The book value reflects the material base for these complex biotechnological developments. The chart shows its physical weight.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Xencor Inc.
Xencor, a biotech company with a platform for antibody engineering, is valued by the market at a multiple of its lab value. Investors are paying for its technology, which enables the creation of more effective drugs, and for its numerous partnerships with major pharmaceutical companies.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Xencor is a biotech company developing antibodies to treat cancer and autoimmune diseases. Its value lies in its XmAb technology platform. The chart shows the high premium investors are paying for its innovative approach to drug development.
Market to book capitalization ratio for the market as a whole
Xencor is a biotech company that developed the XmAb platform for creating improved antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its business model combines proprietary developments with partnerships with major pharmaceutical companies. This metric reflects the premium it places on a technological platform with multiple applications.
Debts of the company, segment and market as a whole
XNCR - Company debts Xencor Inc.
Xencor, a biotech company with a platform for creating improved antibodies, funds its numerous programs through partnership fees and raised capital. Maintaining a strong balance sheet allows the company to leverage debt for tactical flexibility. This chart illustrates its financial strategy aimed at maximizing the potential of its technology.
Market segment debts - Oncology immuno-therapy
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb technology enables the creation of more effective drugs. This chart shows how the company funds its extensive scientific platform and numerous clinical programs, often in partnership with major pharmaceutical companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Xencor Inc.
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb platform requires significant and ongoing investment in R&D. This chart shows how the company uses debt to fund its broad portfolio of clinical and preclinical programs.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Xencor is a biotech company developing antibodies and cytokines to treat cancer and autoimmune diseases using its XmAb platform. This chart shows how the company finances its expensive research and relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Xencor, Inc. is a biopharmaceutical company developing antibodies to treat cancer and autoimmune diseases. Developing innovative drugs requires massive, long-term investments. How much does Xencor rely on debt? This chart of total market debt provides context for assessing its financial strategy and resilience in this risky journey.
P/E of the company, segment and market as a whole
P/E - Xencor Inc.
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. This chart shows how investors value its XmAb technology platform. The valuation depends on the success of its clinical programs and partnerships with major pharmaceutical companies.
P/E of the market segment - Oncology immuno-therapy
Xencor is a clinical-stage biotechnology company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. This chart shows the average valuation for the sector, helping to understand how the market values Xencor's XmAb technology platform and scientific pipeline.
P/E of the market as a whole
Xencor is a biotech company developing antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb platform enables the creation of innovative molecules. Does the company's valuation reflect a general interest in immuno-oncology, or is it a unique bet on its technology and partnerships with major pharmaceutical companies?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Xencor Inc.
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb technology enables the creation of more effective drugs. This chart reflects investors' confidence in the platform's potential. Future profits depend on clinical success and partnerships with major pharmaceutical companies.
%20P%2FE%20Xencor%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Xencor-Inc.&v=1772618284672 "Chart of the company's future (projected) P/E Xencor Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Xencor is a biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb technology enables the creation of more effective drugs. The chart shows forecasts for the oncology sector. This allows us to compare the market's confidence in Xencor's technology platform with its extensive portfolio of partnerships with major pharma.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772618284868 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Xencor, Inc. is a biotech company developing antibodies to treat cancer and autoimmune diseases using its innovative platform. The company's valuation depends on the success of this platform. This market sentiment chart shows how willing investors are to invest in platform biotech companies with long-term potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772618284958 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Xencor Inc.
Xencor, Inc. uses its XmAb technology to create and develop antibodies and cytokines for the treatment of cancer and autoimmune diseases. The company generates revenue from partnerships and royalties. This chart shows how clinical development successes and deals with major pharmaceutical companies impact the financial performance of this innovative biotech.
Profit of companies in the market segment - Oncology immuno-therapy
Xencor is a biotech company using its XmAb platform to create new antibodies and cytokines for the treatment of cancer and autoimmune diseases. This chart, showing profitability in the oncology sector, highlights the potential of immunotherapy. Their technologies enable the development of more effective and safer drugs, attracting partners from major pharmaceutical companies.
Overall market profit
Xencor, Inc. is developing new classes of antibodies for the treatment of cancer and autoimmune diseases using its innovative XmAb technology. The company's progress depends on the success of clinical trials. This gross profitability chart reflects the investment climate, which allows advanced biotech companies like Xencor to raise funds for expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Xencor Inc.
Xencor is a biotech company developing a new generation of antibodies and cytokines for the treatment of cancer and autoimmune diseases using its XmAb platform. This chart summarizes analyst opinions on the potential of their technology platform and the success of numerous partnerships with major pharmaceutical companies.
%20profit%20of%20the%20company%20Xencor%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Xencor-Inc.&v=1772618285107 "Graph of future (projected) profit of the company Xencor Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Xencor, Inc. is a biotech company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Its value lies in its XmAb technology platform and partnerships with major pharmaceutical companies. This chart for the oncology sector illustrates the market's overall confidence in the potential of immunotherapy and new treatment approaches.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772618285139 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Xencor, Inc. is a biotech company developing antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its success depends on science. However, the overall profit outlook reflected in this chart influences the willingness of large pharma companies to enter into partnerships and the overall risk assessment of investors in the sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772618285199 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Xencor Inc.
Xencor is a biotech company developing engineered antibodies to treat cancer and autoimmune diseases. The chart shows the high valuation of each dollar of its revenue from partnerships and royalties. This reflects the value of its XmAb technology platform and investors' confidence in the potential of its multiple clinical programs.
P/S market segment - Oncology immuno-therapy
Xencor, Inc. uses its XmAb protein engineering platform to create bispecific antibodies and cytokines for the treatment of cancer and autoimmune diseases. Revenue comes from partnerships and future sales. This chart reflects the average biotech valuation, helping to understand the premium the market is willing to pay for Xencor's advanced and productive technology platform.
P/S of the market as a whole
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb technology enables the creation of more effective drugs. This chart, which reflects revenue estimates for traditional companies, highlights the premium investors are willing to pay for a cutting-edge scientific platform with the potential to create numerous new drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Xencor Inc.
Xencor is a biotech company developing antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its XmAb platform enables the creation of innovative drugs. This chart reflects investor assessments of the future success of not only its own developments but also the potential revenue from numerous partnerships with major pharmaceutical companies.
%20P%2FS%20Xencor%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Xencor-Inc.&v=1772618285293 "The graph of the company's future (projected) P/S Xencor Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Xencor, Inc. is a biotechnology company using its proprietary XmAb technology to develop a new class of antibodies and cytokines for the treatment of cancer and autoimmune diseases. This chart reflects average revenue expectations in the immuno-oncology sector. It provides insight into the market's appreciation of Xencor's innovative drug discovery platform.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772618285326 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Xencor, Inc. is using its proprietary XmAb technology to create a new generation of antibodies for the treatment of cancer and autoimmune diseases. This chart reflects overall investor sentiment. Xencor's innovative platform is attracting major partners and fueling hopes for the development of more effective and safer drugs, which is one of the growth drivers for the entire biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772618285364 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Xencor Inc.
This chart illustrates the revenue of Xencor, Inc., a biopharmaceutical company that develops and engineers monoclonal antibodies for the treatment of cancer and autoimmune diseases. Its revenue is generated through royalties from partners using its technology and collaboration fees, reflecting the success of its innovative platform.
Sales of companies in the market segment - Oncology immuno-therapy
Xencor, Inc. is a biotechnology company developing engineered antibodies for the treatment of cancer and autoimmune diseases. This chart reflects the growth of the immunotherapy market. Xencor's innovative platform enables the creation of more effective and safer drugs, and its partnerships with major pharmaceutical companies confirm the technology's high potential for creating new treatment standards.
Overall market sales
Xencor, Inc. is a biotech company developing antibodies to treat cancer and autoimmune diseases. Its value is based on the potential of its scientific platform. The overall economic situation, reflected in this chart, influences the willingness of investors and large pharmaceutical companies to fund cutting-edge research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Xencor Inc.
Xencor is a biotech company developing antibodies and cytokines for the treatment of cancer and autoimmune diseases using its XmAb platform. The chart reflects analyst expectations for the success of its clinical programs and partnerships with major pharmaceutical companies.
%20sales%20of%20the%20company%20Xencor%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Xencor-Inc.&v=1772618285572 "Schedule of future (projected) sales of the company Xencor Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Xencor is a biotech company that uses its proprietary XmAb technology to create a new generation of antibodies and cytokines for the treatment of cancer and autoimmune diseases. This chart shows the outlook for the immuno-oncology market, where Xencor's innovative platform enables the creation of more effective and safer drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772618285578 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Xencor, Inc. is a biopharmaceutical company developing antibodies for the treatment of cancer and autoimmune diseases using its XmAb platform. Its valuation is dependent on the success of clinical programs and partnerships. This chart reflects the overall investment climate, but Xencor's research progress is the key driver attracting investors who believe in its technology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772618285644 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Xencor Inc.
Xencor uses its XmAb technology to create and develop antibodies for the treatment of cancer and autoimmune diseases. The company's profitability depends on the success of its own programs and partnerships with major pharmaceutical companies. This chart shows how the company balances R&D costs with partner revenues, monetizing its technology platform.
Market segment marginality - Oncology immuno-therapy
#VALUE!
Market marginality as a whole
Xencor is a biotech company developing new classes of antibodies for the treatment of cancer and autoimmune diseases. Their XmAb technology enables the creation of more effective and "smart" drugs. This overall profitability curve is irrelevant to them. Their value is determined solely by the potential of their scientific platform and success in clinical development.
Employees in the company, segment and market as a whole
Number of employees in the company Xencor Inc.
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Its growing team of scientists drives its innovative R&D platform. This chart reflects its investment in science and the progress of its numerous partnerships and in-house programs.
Share of the company's employees Xencor Inc. within the market segment - Oncology immuno-therapy
Xencor is using its cutting-edge technology to create and develop next-generation antibodies for the treatment of cancer and autoimmune diseases. This chart shows the share of protein engineering talent the company attracts. This growth reflects the expansion of its research programs and strengthening its leadership in creating more effective biologics.
Number of employees in the market segment - Oncology immuno-therapy
Xencor, Inc. is a biopharmaceutical company using its proprietary XmAb technology to create and develop monoclonal antibodies for the treatment of cancer and autoimmune diseases. This chart shows the dynamics of employment in the cutting-edge field of immuno-oncology. The growth in the number of scientists reflects the platform's productivity and progress in clinical trials of a comprehensive portfolio of innovative drugs.
Number of employees in the market as a whole
Xencor is a biotech company developing engineered antibodies to treat cancer and autoimmune diseases. Its XmAb technology enables the creation of more effective and safer drugs. This achievement demonstrates how innovative biotech platforms like Xencor's lay the foundation for an entire drug pipeline and drive scientific employment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Xencor Inc. (XNCR)
Xencor is a biotech company known for its XmAb platform for creating antibodies. This chart is a prime example of intellectual capital valuation. The company's key asset is its technology platform, which enables rapid drug development and optimization. The chart shows how highly the market values this "antibody factory" per scientist.
%20of%20the%20company%20Xencor%20Inc.%20(XNCR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Xencor-Inc.-XNCR&v=1772618285807 "Chart of market capitalization per employee (in thousands of dollars) of the company Xencor Inc. (XNCR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Xencor is a biotech company developing antibodies for the treatment of cancer and autoimmune diseases. Its value is driven by its unique XmAb technology platform. This chart demonstrates the market's high appreciation for its innovative technologies and intellectual property, where a small team of scientists is developing potential blockbusters.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772618285832 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Xencor is a biotech company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. The chart reflects the valuation of its innovative technology platform. The high per-employee price demonstrates that investors value its ability to develop multiple drug candidates, not just a single product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772618285839 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Xencor Inc. (XNCR)
Xencor is a biotech company that uses its proprietary platform (XmAb) to create improved antibodies and cytokines. Their model is not to sell drugs, but to license their technology to big pharma. This chart illustrates the effectiveness of this model: profit per employee can skyrocket when the company receives large upfront or royalty payments.
%20Chart%20Xencor%20Inc.%20(XNCR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Xencor-Inc.-XNCR&v=1772618285856 "Company Profit Per Employee (in thousands of dollars) Chart Xencor Inc. (XNCR)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Xencor (XNCR) is a biotech company developing engineered antibodies (XmAb technology) for the treatment of cancer and autoimmune diseases. They both develop their own drugs and license their technology to partners. This metric reflects the balance between R&D expenses and revenue from partner fees.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772618285900 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Xencor is a biotech company using its platform (XmAb) to create new antibodies (bispecifics) for oncology and autoimmune diseases. It is an R&D company that also licenses its technology. This chart shows how much revenue from partners (royalties) covers its own R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772618285979 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Xencor Inc. (XNCR)
Xencor develops and licenses technologies to create improved antibodies and biotherapeutics. This chart reflects the value of its intellectual property. Revenue per employee growth is driven by royalties and milestone payments from partners, demonstrating the successful application of its XmAb platform to drug discovery.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Xencor-Inc.-XNCR&v=1772618286195 "Sales chart per company employee Xencor Inc. (XNCR)")
Sales per employee in the market segment - Oncology immuno-therapy
Xencor (XNCR) uses its XmAb platform to create "improved" antibodies for the treatment of cancer and autoimmune diseases. This chart shows how productive their R&D team is. It measures revenue (from royalties and partnerships) per scientist, which is an indicator of the effectiveness of their technology platform.
Sales per employee for the market as a whole
Xencor (XNCR) is a biotech company developing antibodies (XmAb technology) for the treatment of cancer and autoimmune diseases. The company generates revenue primarily from partnerships with major pharmaceutical companies. This chart shows how effectively the company's elite scientific staff converts its R&D into revenue from licensing and milestone payments.
Short shares by company, segment and market as a whole
Shares shorted by company Xencor Inc. (XNCR)
Xencor, Inc. is a biotech company developing antibodies (XmAb technology) for the treatment of cancer and autoimmune diseases. It has partnerships with major pharmaceutical companies. This chart shows bearish bets. Investors may doubt the long-term potential of its platform or the success of its numerous early clinical programs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Xencor-Inc.-XNCR&v=1772618286386 "Short Shares Chart for the Company Xencor Inc. (XNCR)")
Shares shorted by market segment - Oncology immuno-therapy
Xencor is a biotech company with the XmAb platform for creating "improved" antibodies (for example, to treat cancer or autoimmune diseases). This indicator reflects skepticism. The "shorts" here represent a bet that their scientific platform will not be able to produce successful commercial drugs.
Shares shorted by the overall market
Xencor develops antibodies to treat cancer and autoimmune diseases using its XmAb platform. When fear rises on this chart, investors dump biotechs. However, Xencor is unique in that it receives royalties from partners (Alexion, Novartis). The market is weighing whether stable payments outweigh the risks of R&D during times of panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Xencor Inc. (XNCR)
Xencor (XNCR) is a biotech company using its XmAb platform to create "improved" antibodies for the treatment of cancer and autoimmune diseases. They have numerous partnerships with big pharma. This chart measures hype. It shows "overbought" (above 70) on news of partnerships or R&D successes, and "oversold" (below 30) amid trial failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Xencor-Inc.-XNCR&v=1772618286496 "RSI 14 indicator chart for the company's stock Xencor Inc. (XNCR)")
RSI 14 Market Segment - Oncology immuno-therapy
Xencor (XNCR) is a biotech company that engineers antibodies. Their platform (XmAb) reengineers antibodies to treat cancer and autoimmune diseases. RSI_14_Seg for "Oncology" (biotech) reflects the overall sentiment. It helps us understand whether XNCR's volatility is a reflection of their platform or the general hype in the sector.
RSI 14 for the overall market
Xencor (XNCR) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XNCR (Xencor Inc.)
Xencor is a biotech company using its XmAb platform to create "smart" antibodies for the treatment of cancer and autoimmune diseases. They both license their technology and conduct their own development. This chart shows the average 12-month analyst forecast, reflecting their assessment of the potential of the XmAb platform and revenue from partners.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XNCR-Xencor-Inc.&v=1772618286591 "A chart showing analyst consensus forecasts for the expected stock price. XNCR (Xencor Inc.)")
The difference between the consensus estimate and the actual stock price XNCR (Xencor Inc.)
Xencor (XNCR) is a biotech company that developed the XmAb platform for creating improved (bispecific) antibodies. It licenses this technology to giants (receiving royalties) and conducts its own R&D in oncology. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XNCR-Xencor-Inc.&v=1772618286618 "A chart showing the difference between the consensus forecast and the actual stock price. XNCR (Xencor Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Xencor (XNCR) is a biotech company with a toolkit (the XmAb platform) for creating improved bispecific antibodies for the treatment of cancer and autoimmune diseases. This chart shows general expectations for the immunotherapy sector, reflecting experts' confidence in the strength of this R&D platform.
Analysts' consensus forecast for the overall market share price
Xencor is an R&D biotech specializing in immuno-oncology (bispecific antibodies). They're burning through cash. This chart, reflecting the economic consensus, is their risk appetite. If the consensus is negative (downturn), investors flee cash-burning, pre-profit biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Xencor Inc.
Xencor is an engineering biotech company. Their signature feature is their XmAb R&D platform, which allows them to tune antibodies, making them more potent or bispecific (attacking two targets). This chart is an indicator of their platform. It likely aggregates their partnership revenue (with big pharma) and the market's confidence in their own, internal R&D pipeline.
AKIMA Market Segment Index - Oncology immuno-therapy
Xencor (XNCR) is an oncology biotech innovator; the company uses its unique R&D platform (XmAb) to create bispecific antibodies (smart drugs), which it licenses to giants (Novartis, Gilead). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this technologically advanced (fintech R&D) model (XNCR) differentiate it from the average pharma company?
The AKIM Index for the overall market
Xencor is a biopharmaceutical company developing engineered antibodies (XmAb technology) for the treatment of cancer and autoimmune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this platform, which licenses its technology to giants, compares to overall economic trends.
